PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

Positive results for Amphera’s MesoPher cell therapy

Treatment demonstrated significant survival data in addition to a sustained safety profile.

Amphera – a company developing MesoPher cell therapy to treat cancer – has delivered positive results from its phase 2 Reactive trial and phase 2/3 DENIM trial.

During the phase 2 Reactive study, patients with resected pancreatic cancer who had completed standard-of-care chemotherapy received three bi-weekly injections of Amphera’s MesoPher dendritic cell therapy along with booster injections at four- and seven-month intervals.

The research met the primary endpoint with efficacy and safety data from two cohorts across a study of 38 patients. This demonstrated a statistically significant two-year recurrence-free survival of 60% as well as excellent safety.

Meanwhile, in the DENIM trial, mesothelioma patients with the stable disease received either MesoPher maintenance treatment or the best supportive care available. The study also involved identical dosing to the Reactive trial.

The study reinforced MesoPher’s sound safety profile, while also demonstrating the therapy’s ability to induce a robust T-cell response. The immune response, however, did not translate into clinical benefit and therefore the primary endpoint of improved overall survival was not met.

This could be attributed to two main factors – the majority of patients were already progressive before or during the first 3 bi-weekly injections, while only a small proportion of patients actually received the full MesoPher treatment.

Professor Casper van Eijck, a principal investigator of the Reactive trial, commented: “We are thrilled by the promising results of the Reactive trial. The results exceed expectations for this group of patients compared to the best current treatments. A 60% 2-year recurrence-free survival after surgical resection truly is an exceptional outcome.”

“Further randomised clinical research with MesoPher in pancreatic cancer is a likely next step. In addition, we have seen that MesoPher induces a T-cell response against the tumour of patients, which could explain the efficacy, although pancreatic cancer is known as a cold tumour,” he added.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026